Journal of Drug Targeting

Papers
(The H4-Index of Journal of Drug Targeting is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
A comprehensive review on the antiviral activities of chalcones62
CRISPR-cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia56
Mesoporous silica nanoparticles: synthesis methods and their therapeutic use-recent advances51
Carbon-based nanomaterials for targeted cancer nanotherapy: recent trends and future prospects50
A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances34
New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease32
Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-1931
Improved oral delivery of quercetin with hyaluronic acid containing niosomes as a promising formulation31
Stability issues and approaches to stabilised nanoparticles based drug delivery system29
Non-surgical osteoarthritis therapy, intra-articular drug delivery towards clinical applications28
The relevant targets of anti-oxidative stress: a review28
3D printing technology in healthcare: applications, regulatory understanding, IP repository and clinical trial status28
Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications28
Targetting ferroptosis for blood cell-related diseases27
Manganese dioxide (MnO2) based nanomaterials for cancer therapies and theranostics27
ABC transporters in breast cancer: their roles in multidrug resistance and beyond26
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety26
Fabrication and characterisation of self-applicating heparin sodium microneedle patches26
Current status of micro/nanomotors in drug delivery25
Potential inhibitors of SARS-CoV-2: recent advances24
Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumours24
Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide24
Active-site molecular docking of nigellidine with nucleocapsid–NSP2–MPro of COVID-19 and to human IL1R–IL6R and strong antioxidant role of Nigella sativa in experimental rats23
0.038969993591309